BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18339845.
- Also identified by DOI 10.1158/0008-5472.CAN-07-5276 and PMC identifier 2915562.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Screening for tumor suppressor genes in breast cancer revealed multiple truncating mutations of PB1, which encodes the BAF180 subunit of the PBAF chromatin remodeling complex. Mutation was associated with loss of heterozygosity of the wild-type allele. BAF180 complementation of BAF180-mutant tumor cells caused G(1) arrest that was dependent on increased expression of the cyclin/cyclin-dependent kinase inhibitor p21/WAF1/CIP1. Endogenous wild-type BAF180 bound to the p21 promoter and was required for proper p21 expression and G(1) arrest after transforming growth factor-beta and gamma-radiation treatment. BAF180 thus functions on two tumor suppressor signaling pathways as a physiologic mediator of p21 expression. We conclude that BAF180 suppresses tumorigenesis, at least in part, through its ability to regulate p21.
Medical subject headings
- Breast Neoplasms
- Cyclin-Dependent Kinase Inhibitor p21
- Nuclear Proteins
- Transcription Factors